© 2023 Cellaïon
Wallonie Entreprendre is a public regional promotional institution for the Belgian region of Wallonia founded in 2002.
Visit Wallonie entreprendre
SMS Investments SA is a consultancy firm specializing in management and investment services. It is a foreign entity that was incorporated on October 1, 2012, in Belgium. The company is dedicated to utilizing its expertise in capital markets to assist its clients in realizing their financial objectives and aspirations.
Fund+ is an open-ended fund that invests in innovative life sciences companies with a focus on Belgium. The fund was founded in 2015 and is based in Leuven, Belgium. Fund+ aims to create sustainable investments in long-term equity. The fund prefers to invest in seed-stage, early-stage, and later-stage companies.
Group of private investors who have decided to personally invest in our project because they believe in our vision and our ability to achieve our goal.
Invest.BW is a venture capital firm based in Louvain-la-Neuve, Belgium. The firm primarily makes seed and start-up investments in the early-stage. Invest.BW is an incubator and an early-stage venture capital firm. It has invested in three portfolio startups. The firm is focused on investing in innovative companies and is located in Baden-Württemberg, Germany
Shinsei Capital Partners (SCP) is a Japanese VC firm specialized in cutting edge biotechnologies for patients. SCP’s mission is to help such research outcomes to be funded and to catalyze the translation of innovative medicines serving the needs of the patients. SCP contributes to the most promising technology innovations through the hands-on leverage of their deep knowledge of the sector and unique experiences in finance and drug development.
The Walloon Region, The Walloon Region – Belgium (DGO6) granted subsidies to Cellaïon to develop its signaling cell technology and conduct clinical studies for targeted indications.
L’Agence Wallonne à l’Exportation et aux Investissements Étrangers (AWEX) – Belgium supports the international development of Cellaïon.
Cellaïon has an ongoing collaboration with the founding Laboratory of Pediatric Hepatology and Cellular Therapy of the Experimental Clinical and Research Institute (IREC, PEDI pole) at UCLouvain, Brussels, Belgium.
The Walloon regional government
AWEX, which promotes foreign trade and investments in Wallonia.
BioWin , the driving force for medical biotechnology and health technology growth in Wallonia.
Furthermore, Belgium’s location in the heart of Europe facilitates exceptional transport links across the world, providing an ideal infrastructure for the distribution of goods from our manufacturing sites to treatment centers.
Cellaïon is looking to use its outstanding capabilities and expertise in liver biology and cell-based medicine, along with its strong scientific, preclinical and early-stage clinical development expertise, to build strategic collaborations .
Do you want to know more?
Send us an email
QA ANALYST – GcP
Cellaïon SA is currently hiring a QA Analyst – GcP.
– Writing of general quality system procedures to support business objectives and comply with regulatory requirements for clinical, production, logistics, QA and QC activities.
– Review and evaluate production batch and QC files (batch records, certificates of analysis and compliance, etc.) prior to the release of clinical batches.
– Manage and update quality assurance system documents.
More Info? Please, download the Job description!
A new article on the Multi-Target Effect of HALPCs in the NASH STAM model has recently been published in Cells Journal. “Human Allogeneic Liver-Derived Progenitor Cells Significantly Improve NAFLD Activity Score and Fibrosis in Late-Stage NASH Animal Model”. Cells is an international, peer-reviewed, open access journal of cell biology, molecular biology, and biophysics This peer-reviewed publication recognizes HALPCs as part of the most recent advances in liver repair strategies. This article is the first to show the results of the in vitro and in vivo properties of HALPCs.
A phase II study of human allogeneic liver-derived progenitor cell therapy for acute-on-chronic liver failure and acute decompensation
Phase I/II Trial of Liver–derived Mesenchymal Stem Cells in Pediatric Liver–based Metabolic Disorders
The new Walloon company Cellaïon makes its first closing.
Cellaion SA announces a total fundraising of EUR 23 million in 2022.
Cellaion SA announces the arrival of Walid Abi-Saab in its Board of Directors, the hiring of Griet Goddemaer to lead clinical development and the green light from the DSMB for the continuation of ACLF- Dheliver Clinical trial.